跳到正文
原文
Medical Xpress·· 23 天前精选AI 评分66

三氧化二砷联合地西他滨恢复突变p53,试点试验中4/5例AML/MDS达完全分子学缓解

Arsenic drug combo resurrects 'guardian of the genome' to fight aggressive blood cancers

AI 导读

上海血液学研究所团队在Science Translational Medicine报告,三氧化二砷联合地西他滨在5例p53突变急性髓系白血病(AML)和骨髓增生异常综合征(MDS)的试点试验中,使4例达到完全分子学缓解。

推荐理由

5例p53突变AML/MDS患者中4例达完全分子学缓解,研究按突变类型筛选潜在获益人群。

正文
dna
Credit: CC0 Public Domain

A combination cancer therapy that relies on the reactivation of a tumor suppressor protein to kill leukemic and other blood cancer cells has shown promise in a small pilot trial.

Medical investigators at the Shanghai Institute of Hematology in China are working to restore activity to the p53 protein, the product of the TP53 gene. The protein is mutated in nearly half of all human cancers, and that ubiquity has long made p53 a highly attractive target for novel anticancer therapies.

In the public eye for decades, the p53 protein has an exceptionally long and storied past. Although it was originally discovered in its mutated form—which led to the mistaken belief that it was a cancer-promoting oncogene—researchers eventually learned its actual, protective identity.

Guardian of the genome

After that discovery, scientists began calling it "the guardian of the genome," and the hunt was on to find a drug capable of returning it to a healthy state. In 1993, its unmutated form was named Molecule of the Year by Science Magazine, celebrating its vital role as a natural tumor suppressor.

Over the years, scientists have developed dozens of small molecules with the aim of targeting p53 mutants and restoring their tumor-suppressing capabilities. However, few have led to genuine clinical benefits.

New research reported in Science Translational Medicine suggests that an arsenic-based medication, used in combination with the established cancer drug decitabine, might finally deliver a substantial impact. Decitabine promotes DNA demethylation and is already widely used against cancers of the blood.

Dr. Huaxin Song and colleagues launched both laboratory studies and clinical research to test this combination therapy against aggressive acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) bearing mutant p53 proteins. In these specific blood cancers, p53 mutations result in the inactivation of the protein and are heavily associated with aggressive disease progression.

Arsenic drug combo restores mutated protein

"Arsenic trioxide may be effective in restoring function to p53 structural mutants," Song, the lead author of the research, wrote in the journal. Song further noted that "mutant p53 rescued by arsenic trioxide treatment strengthened interferon responses triggered by the DNA hypomethylating agent decitabine."

It was the potentially potent anticancer properties of p53 that inspired the Shanghai team to attempt resurrecting it. Prior to the pilot study, the investigators tested arsenic trioxide and decitabine against cancer cell lines and mouse models.

The drug combination successfully killed cancer cells by transforming the mutants back into active tumor suppressors. This, in turn, improved the disease's vulnerability to decitabine and enhanced the expression of the IRF7 gene, which fine-tunes the body's immune interferon responses.

Going into the pilot trial, Song and the Shanghai team carefully selected patients with specific p53 mutations that they knew stood the strongest chances of being reversed by the dual-drug regimen. The strategy paid off: the scientists reported a complete molecular remission in four of the five treated patients.

Since the trial, the researchers have collected data on a wider variety of p53 mutations to determine which ones will most likely respond to the arsenic trioxide–decitabine therapy.

"In 103 p53-mutant patients whose samples were deposited in the Ruijin AML/MDS sample repository, 48 distinct p53 missense mutants were identified," Song wrote. "Of these, 21 were classified as arsenic trioxide and decitabine regimen applicable because of their competencies in activating p53 and interferon responses upon cotreatment."

Based on the data collected so far, the researchers believe they have successfully laid the foundation for a targeted anticancer therapy tailored to the presence of specific p53 mutations.

"This study establishes an alternative treatment regimen for patients with p53-mutant AML/MDS," Song concluded, "and provides a proof-of-concept framework for p53-targeted therapy that differentiates between p53 mutations."

Written for you by our author Delthia Ricks, edited by Sadie Harley, and fact-checked and reviewed by Robert Egan—this article is the result of careful human work. We rely on readers like you to keep independent science journalism alive. If this reporting matters to you, please consider a donation (especially monthly). You'll get an ad-free account as a thank-you.

Publication details

Huaxin Song et al., Mutant p53 reactivation and DNA demethylation in the treatment of AML/MDS, Science Translational Medicine (2026). DOI: 10.1126/scitranslmed.ads9325

Journal information: Science Translational Medicine

Clinical categories

Oncology

Who's behind this story?

Delthia Ricks

Delthia Ricks

Award-winning science writer published in Newsday and Discover Magazine. Author of four books. UCLA and Columbia graduate. Full profile →

Sadie Harley

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

© 2026 Science X Network

Citation: Arsenic drug combo resurrects 'guardian of the genome' to fight aggressive blood cancers (2026, October 28) retrieved 28 October 2026 from https://medicalxpress.com/news/2026-10-arsenic-drug-combo-resurrects-guardian.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com